Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Sell

Analyst Rating

Strong Sell

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Neutral

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

Alterity Therapeutics Limited American Depositary Shares (ATHE)

https://www.alteritytherapeutics.com

Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

09/05/2002

Market Cap

14,855,977

Shares Outstanding

3,811,330,000

Weighted SO

4,066,496

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

ANEB --.--%

PMVP --.--%

ANTX --.--%

ELYM --.--%

HCWB --.--%

TARA --.--%

VCNX --.--%

MNPR --.--%

MIRO --.--%

Beta

0.7110

Last Div

0.0000

Range

1.01-5.41

Chg

-0.0020

Avg Vol

34300

Mkt Cap

14855977

Exch

NASDAQ

Country

AU

Phone

61 3 9349 4906

DCF Diff

1.4530

DCF

-0.0730

Div Yield

0.0000

P/S

0.0000

EV Multiple

0.0000

P/FV

0.0000

Div Yield %

0.0000

P/E

0.0000

PEG

0.0000

Payout

0.0000

Current Ratio

6.1727

Quick Ratio

5.5863

Cash Ratio

3.5997

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

0.0000

CCC

0.0000

Gross Margin

0.0000

Op Margin

0.0000

Pretax Margin

0.0000

Net Margin

0.0000

Eff Tax Rate

0.0000

ROA

0.0000

ROE

0.0000

ROCE

0.0000

NI/EBT

0.0000

EBT/EBIT

0.0000

EBIT/Rev

0.0000

Debt Ratio

0.0077

D/E

0.0092

LT Debt/Cap

0.0045

Total Debt/Cap

0.0091

Int Coverage

0.0000

CF/Debt

-49.9678

Equity Multi

1.1975

Rec Turnover

0.0000

Pay Turnover

0.0000

Inv Turnover

0.0000

FA Turnover

0.0000

Asset Turnover

0.0000

OCF/Share

0.0000

FCF/Share

0.0000

Cash/Share

0.0000

OCF/Sales

0.0000

FCF/OCF

1.0003

CF Coverage

-49.9678

ST Coverage

-98.0846

CapEx Coverage

-3061.2743

Div&CapEx Cov

-3061.2743

P/BV

0.0000

P/B

0.0000

P/S

0.0000

P/E

0.0000

P/FCF

-2.1225

P/OCF

0.0000

P/CF

0.0000

PEG

0.0000

P/S

0.0000

EV Multiple

0.0000

P/FV

0.0000

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jun 12, 23:22 Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar GlobeNewswire Inc. Jan 22, 07:25 Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones GlobeNewswire Inc. Dec 21, 00:30 Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer GlobeNewswire Inc. Dec 21, 00:30 Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer GlobeNewswire Inc. Dec 21, 00:30 Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer GlobeNewswire Inc. Dec 04, 16:35 Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress GlobeNewswire Inc. Dec 04, 07:25 Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease GlobeNewswire Inc. Nov 27, 07:25 Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy GlobeNewswire Inc. Nov 16, 07:25 Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434 GlobeNewswire Inc. Oct 30, 07:25 Appendix 4C – Q1 FY24 Quarterly Cash Flow Report

Revenue Product Segmentation